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Abstract 36 
Background 37 
NK cells are activated by innate cytokines and viral ligands to kill virus-infected cells; 38 
these functions are enhanced during secondary immune responses and after 39 
vaccination by synergy with effector T cells and virus-specific antibodies. In human 40 
Ebola virus infection, clinical outcome is strongly associated with the initial innate 41 
cytokine response, but the role of NK cells has not been thoroughly examined.  42 
Methods 43 
The novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and 44 
modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and 45 
provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 46 
3 studies. Here, we analysed NK cell phenotype and function in response to 47 
Ad26.ZEBOV, MVA-BN-Filo vaccination regimen, and in response to in vitro Ebola 48 
glycoprotein stimulation of PBMC isolated before and after vaccination.  49 
Results 50 
We show enhanced NK cell proliferation and activation after vaccination compared 51 
with baseline. Ebola glycoprotein-induced activation of NK cells was dependent on 52 
accessory cells and TLR-4-dependent innate cytokine secretion (predominantly from 53 
CD14+ monocytes) and enriched within less differentiated NK cell subsets. Optimal 54 
NK cell responses were dependent on IL-18 and IL-12, whilst IFN-γ secretion was 55 
restricted by high concentrations of IL-10.  56 
Conclusion 57 
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This study demonstrates the induction of NK cell effector functions early after 58 
Ad26.ZEBOV, MVA-BN-Filo vaccination and provides a mechanism for the activation 59 
and regulation of NK cells by Ebola GP.  60 
Trial registration 61 
ClinicalTrials.gov Identifier: NCT02313077 62 
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and innovation programme and European Federation of Pharmaceutical Industries 67 
and Associations (EFPIA).  68 
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Introduction 69 
Ebola virus infection causes a rapid onset, severe acute haemorrhagic fever (Ebola 70 
virus disease, EVD) with mortality ranging from 25% to 90% depending on the 71 
outbreak (1). Clinical development of effective vaccines remains a high priority as 72 
regular disease outbreaks continue on the African continent, and there is still no 73 
licensed product. Ebola vaccine development has focused on the viral glycoprotein 74 
(GP), the only protein exposed on the surface of the mature virus particle; Ebola virus 75 
GP is essential for viral entry into host cells and is highly immunogenic (2, 3). Studies 76 
of a GP expressing recombinant vesicular stomatitis virus (rVSV) vaccine have shown 77 
that immunity directed against this protein confers protection (4). A 2-dose vaccination 78 
approach with adenovirus type 26 expressing the Zaire Ebola virus GP (Ad26.ZEBOV) 79 
and modified vaccinia Ankara expressing ZEBOV, Sudan Ebola virus and Marburg 80 
virus GP and Tai Forest Ebola virus nucleoprotein (MVA-BN-Filo), has been shown to 81 
be safe and immunogenic in phase 1 clinical trials, eliciting robust and persistent 82 
antibody concentrations and antigen specific T cell responses (5-9). The 83 
Ad26.ZEBOV, MVA-BN-Filo vaccine regimen is currently being evaluated in Phase 2 84 
and 3 clinical studies. 85 
Innate immune dysregulation underlies the pathophysiology of EVD resulting in failure 86 
to activate essential effector cell functions and consequent uncontrolled virus 87 
replication, systemic virus dissemination and inflammation (2, 10). Ebola virus infects 88 
macrophages and DCs impairing maturation and the type I IFN response due in part 89 
to the presence of interferon inhibiting domains (IIDs) within viral proteins, VP24 and 90 
VP35. In vitro studies with human peripheral blood mononuclear cells (PBMC) have 91 
shown that DC maturation, type I IFN secretion and NK cell activation are all enhanced 92 
when these Ebola virus IIDs are mutated (11, 12). Impairment of the type I IFN 93 
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response is accompanied by an excessive pro-inflammatory cytokine response (2, 13). 94 
In vitro studies have shown that the Ebola virus GP is a potent ligand for TLR-4 and 95 
induces activation of non-infected monocytic cell lines, monocyte-derived DCs and 96 
macrophages to produce cytokines (14-18). Importantly, an initial type I IFN response 97 
accompanied by modest and transient IL-1β and TNF-α secretion correlated with 98 
survival among EVD patients, whereas high IL-10 was associated with fatal outcome 99 
(13, 19, 20). This indicates that the earliest interactions between the Ebola virus and 100 
the host immune system are critical for determining the outcome of infection.   101 
Non-clinical studies have suggested that, if they can be appropriately activated, NK 102 
cells may potentially play a role in vaccine-induced protection from EVD. For example, 103 
murine infection with Ebola virus fails to induce an NK cell response, whereas 104 
treatment of mice with Ebola GP virus-like particles (VLPs) confers complete 105 
protection against a lethal Ebola virus infection just 3 days later; this protection was 106 
lacking after in vivo NK cell ablation (10). Furthermore, NK cell cytotoxicity and IFN-γ 107 
secretion have been implicated in the prolonged survival of NK cell-sufficient mice 108 
immunised with the rVSV-vectored Ebola virus GP vaccine compared with NK cell-109 
depleted mice (21). In humans, upregulation of the activation markers NKG2D and 110 
CD38 on NK cells was noted within 24 hours of vaccination with the rVSV-ZEBOV 111 
vaccine (22). When taken together with evidence from non-human primates of partial 112 
protection against live virus within 3 days of vaccination and full protection within 7 113 
days, this suggests that NK cells may be able to mediate rapid and effective protection 114 
against Ebola virus (4, 23). Moreover, after vaccination, NK cells may synergise with 115 
anti-GP antibodies to clear virus-infected cells via antibody-dependent cellular 116 
cytotoxicity (ADCC) (24, 25). 117 
 7 
Here, we evaluate the effect of the 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination 118 
regimen on accessory cell cytokine secretion, NK cell phenotype and NK cell effector 119 
function both ex vivo and in response to restimulation in vitro with soluble Ebola virus 120 
GP (EBOV GP). We find that vaccination with Ad26.ZEBOV, MVA-BN-Filo induces 121 
proliferation and activation of less differentiated NK cell subsets as measured ex vivo. 122 
We also find that stimulation of PBMC (collected either before or after vaccination) 123 
with EBOV GP induces TLR-4 dependent secretion of high concentrations of 124 
inflammatory cytokines, mainly from CD14+ monocytes and accessory cell-dependent 125 
NK cell activation. EBOV GP induced NK cell activation was inhibited by neutralising 126 
antibodies to IL-18 (and IL-12) and was enhanced by IL-10 receptor blockade. These 127 
studies further our understanding of innate immune responses to Ebola virus GP 128 
stimulation and suggest NK cells could potentially play a role in early Ad26.ZEBOV, 129 
MVA-BN-Filo vaccine regimen-induced immune responses.  130 
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Results 131 
Robust NK cell responses to Ad26.ZEBOV, MVA-BN-Filo vaccination regimen 132 
measured ex vivo. 133 
Vaccination with several anti-viral vaccines, including influenza, has been shown to 134 
promote NK cell activation and a realignment of subsets associated with functional 135 
differentiation (26-28). We therefore analysed the effect of Ad26.ZEBOV, MVA-BN-136 
Filo vaccination on NK cell activation and subset distribution. Ex vivo flow cytometric 137 
analysis of CD56+CD3- NK cells from pre-vaccination (visit 0), post-dose 1 (visit 1) and 138 
post-dose 2 (visit 2) samples was performed. NK cells were divided into CD56bright, 139 
CD56dimCD57- and CD56dimCD57+ (or total CD56dim) subsets (CD56bright representing 140 
the least differentiated and CD56dimCD57+ the most differentiated subset) (29). The 141 
expression of Ki67 (a cell cycle marker of proliferation), IL-2Rα-chain (CD25, a 142 
component of the IL-2R complex and marker of activation) and NK cell receptors 143 
NKG2A and NKG2C was analysed for each subset (the flow cytometry gating 144 
strategies are shown in Supplementary Figure 1a). Initially, samples from all five 145 
vaccination groups (groups 1 and 2; MVA-BN-Filo on day 1 and Ad26.ZEBOV on 146 
either day 29 or 57 respectively, groups 3, 4 and 5; Ad26.ZEBOV on day 1 and MVA-147 
BN-Filo on days 29, 57 or 15 respectively) were pooled for analysis.  148 
When data for all vaccination groups were combined, there was a significant increase 149 
in the representation of CD56bright NK cells within total NK cells and a corresponding 150 
decrease in the frequency of CD56dim NK cells across vaccination visits (Figure 1a). 151 
CD56bright NK cells had the highest intrinsic capacity to proliferate, reflected in the 152 
higher percentage expression of Ki67 in this subset (Figure 1b), followed by 153 
CD56dimCD57- cells. There was a significant increase in the frequency of CD56bright 154 
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Ki67+ and CD56dimCD57- Ki67+ NK cells between visit 1 and visit 2, suggesting that 155 
proliferation of less differentiated NK cells may explain their increasing frequency (as 156 
in Figure 1a). There was no significant change in the proportion of more highly 157 
differentiated (CD56dimCD57+) NK cells expressing Ki67 (Figure 1b). 158 
Consistent with the expression of the inhibitory receptor NKG2A on less differentiated 159 
NK cell subsets, a significant increase in frequency of NK cells expressing NKG2A 160 
was observed at visit 2, with no significant change in expression of the corresponding 161 
activating receptor, NKG2C (Figure 1c). There was a small but significant increase 162 
between visits 1 and 2 in the percentage of CD56dim (but not CD56bright) NK cells 163 
expressing CD25 (median 0.73% at visit 1; 0.86% at visit 2) (Figure 1d). The proportion 164 
of CD25+ NK cells was positively correlated with the frequency of proliferating (Ki67+) 165 
NK cells 21 days post-dose 2, further suggesting an association between NK cell 166 
activation and proliferation in response to vaccination (Figure 1e). No effect of 167 
vaccination was observed on the percentage or mean fluorescence intensity (MFI) of 168 
NK cells expressing CD16 (the low affinity IgG receptor III, FcγRIII) (Supplementary 169 
Figure 1b). These data indicate proliferation of less differentiated NK cells in response 170 
to Ad26.ZEBOV, MVA-BN-Filo vaccination. 171 
Overall, no significant changes in ex vivo NK cell phenotype and function were 172 
observed after the primary vaccination but significant NK cell proliferation and CD25 173 
expression were observed after the secondary vaccination but with a diversity of 174 
responses among individuals. To investigate any effects of the order and/or interval of 175 
the 2 doses, NK cell responses were reanalysed by vaccination group. Increasing 176 
CD56bright and decreasing CD56dim NK cell frequencies after vaccination was indicated 177 
by a trend in all groups except group 4 (Ad26.ZEBOV followed by MVA-BN-Filo at day 178 
57) and reached significance by one-way ANOVA across vaccination visits in groups 179 
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3 and 5 only (Ad26.ZEBOV followed by MVA-BN-Filo at day 29 and 15 respectively) 180 
(Supplementary Figure 2a, b). Furthermore, there was a significant increase in 181 
CD56bright Ki67+ and CD56dim CD25+ NK cells between baseline and post-dose 2 in 182 
group 4 only (Supplementary Figure 2c, d). These data suggest that the Ad26.ZEBOV, 183 
MVA-BN-Filo vaccine regimen induced a more robust NK cell response than MVA-BN-184 
Filo, Ad26.ZEBOV regimen. However, these effects were small and this subgroup 185 
analysis may lack statistical power due to small numbers of participants.  186 
 187 
NK cell CD107a and CD25, but not IFN-γ upregulation in response to EBOV GP 188 
stimulation in vitro. 189 
To determine the effect of Ad26.ZEBOV, MVA-BN-Filo vaccination regimen on NK cell 190 
responses to soluble EBOV GP, baseline, visit 1 and visit 2 PBMCs were cultured for 191 
8 and 18 hours with 10μg/ml EBOV GP. Frequencies of NK cells expressing CD107a 192 
and IFN-γ (at 8 hours) or CD25 and CD16 (at 18 hours) were analysed by flow 193 
cytometry (gating strategies are shown in Figure 2a). There were no significant 194 
differences in response to EBOV GP between vaccination groups (Supplementary 195 
Figure 2e-g), therefore, all five vaccination groups were combined for analysis. In vitro 196 
stimulation with EBOV GP induced a significant increase in the proportion of NK cells 197 
expressing CD107a (Figure 2b) and CD25 (Figure 2c) at the cell surface compared 198 
with unstimulated cultures (medium alone). EBOV GP stimulation had no effect on NK 199 
cell IFN-γ (at 8 or 18 hours) or CD16 expression (Figure 2d, e). The effect of EBOV 200 
GP on markers of NK cell function did not differ across vaccination visits (Figure 2b-e) 201 
suggesting the effect of EBOV GP on NK cells is independent of vaccine-induced T 202 
cell and antibody responses.   203 
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Given that there was no effect of vaccination on the NK response to EBOV GP, the 204 
analysis of NK cell function by differentiation subset was restricted to the baseline data 205 
set (Figure 3). This analysis revealed that IFN-γ secretion was restricted to the less 206 
differentiated CD56bright and CD56dimCD57- subsets and that significant induction of 207 
IFN-γ by EBOV GP was detected only within the CD56dimCD57- subset (Figure 3a). 208 
By contrast, CD107a and CD25 upregulation in response to EBOV GP was seen in all 209 
NK cell subsets (Figure 3b, c), with a significantly higher CD25 expression in the 210 
CD56bright subset compared with CD56dim subsets (Figure 3c). The majority of CD25+ 211 
NK cell events were CD56dimCD57- (60.5%) (Figure 3d). Overall, these data 212 
demonstrate that EBOV GP induces markers associated with NK cell cytotoxicity 213 
(CD107a) and activation (CD25), with a much lesser impact on IFN-γ secretion, and 214 
that these responses are not enhanced by vaccination.  215 
 216 
High concentrations of inflammatory cytokines induced by EBOV GP in vitro. 217 
NK cells are able to respond to cytokines secreted from activated accessory cells in 218 
response to viral stimuli. To quantify cytokine production in response to EBOV GP 219 
stimulation, baseline and 21-day post-dose 2 vaccination PBMC samples were 220 
stimulated with EBOV GP in vitro for 18 hours and cytokine concentrations in cell 221 
supernatants were measured by Luminex. EBOV GP induced secretion of high 222 
concentrations of IL-10, IL-1β, IFN-α2, GM-CSF, TNF-α and IFN-γ from PBMCs at 223 
baseline and post-dose 2 samples compared with medium alone, where minimal 224 
concentrations were observed (Figure 4). Particularly high concentrations of IL-10 225 
(median 3142pg/ml at baseline), IL-1β (median 1299pg/ml at baseline), GM-CSF 226 
(median 465pg/ml at baseline) and TNF-α (median 5480pg/ml at baseline) were 227 
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measured in response to EBOV GP (Figure 4a, b, d, e). IFN-α2 secretion was also 228 
significantly enhanced by EBOV GP however the absolute concentrations of this 229 
cytokine were low (median 6.1pg/ml at baseline) compared with the other myeloid cell-230 
derived cytokines (Figure 4c). Similarly, a low concentration of IL-12(p70) (maximum 231 
6.6pg/ml) was detectable by Luminex in only a small number of individuals (13 of 71 232 
at baseline and 9 of 71 at post-dose 2; not shown). Conversely, there was no increase 233 
in IP-10 secretion over medium alone and IL-15 was not detected (not shown).  234 
With the exception of a small but significant reduction in EBOV GP-induced TNF-α 235 
concentration in cultures of post-dose 2 PBMCs (4555pg/ml post-dose 2; 5480pg/ml 236 
at baseline) (Figure 4e), there was no overall effect of vaccination on cytokine 237 
concentrations. When vaccination groups were analysed separately, concentrations 238 
of GM-CSF in group 3, IFN-α2 in group 4 and TNF-α in group 5 were significantly 239 
reduced at visit 2 compared with baseline (Supplementary Figure 3c, d, e) suggesting 240 
that reductions in cytokine responses were limited to Ad26.ZEBOV, MVA-BN-Filo 241 
vaccine regimen. In summary, EBOV GP stimulated the release of high concentrations 242 
of IL-10, IL-1β, GM-CSF and TNF-α from PBMCs, indicative of myeloid cell activation, 243 
with lower concentrations of IFN-α2, IL-12 and IFN-γ detected.  244 
 245 
Myeloid accessory cell cytokine-dependent NK cell activation. 246 
Vaccination independent activation of less differentiated, cytokine-responsive NK cell 247 
subsets accompanied by high levels of myeloid cell-derived cytokine secretion, led us 248 
to hypothesise that the NK cell response to EBOV GP is a function of indirect NK cell 249 
activation. To test this hypothesis, we compared IFN-γ, CD107a and CD25 expression 250 
in response to EBOV GP among PBMCs, purified NK cells and purified NK cells in the 251 
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presence of a 1:1 ratio of CD14+ monocyte-enriched cells from healthy (non-252 
vaccinated) control subjects (Figure 5a-c). Expression of CD107a, IFN-γ and CD25 in 253 
the CD56bright NK cell population (in which significant induction was measured) were 254 
determined by flow cytometry as before. IFN-γ, CD107a and CD25 expression was 255 
significantly reduced in purified NK cells compared with whole PBMC suggesting that 256 
accessory cell-derived stimuli are required for optimal NK cell responses to EBOV GP 257 
(Figure 5a-c). CD107a and CD25 responses were recovered in all individuals after 258 
adding back the enriched CD14+ monocyte fraction (Figure 5b-c), suggesting this 259 
population of cells supports NK cell function after EBOV GP stimulation; NK cell IFN-260 
γ expression was not consistently recovered after adding back CD14+ cells (Figure 261 
5a). 262 
To determine the precise nature of the accessory cell-dependent stimuli that drive NK 263 
cell responses to EBOV GP, whole PBMCs from (non-vaccinated) control subjects 264 
were stimulated with EBOV GP in the presence of neutralising antibodies to IL-2, IL-265 
12, IL-15, IL-18 and IFN-αβR2. The blockade of IL-18 significantly reduced the 266 
frequency and MFI of NK cell CD25 expression (Figure 5d, e, Supplementary Figure 267 
4a), with blockade of IL-12 also significantly reducing CD25 expression within the 268 
CD56bright NK cell subset (Figure 5f, g). CD107a expression was also impaired by IL-269 
18 blockade, reflected in the CD56bright and CD56dimCD57- subsets (Figure 5h, 270 
Supplementary Figure 4a). There was no effect of IL-12 or IL-18 blockade on NK cell 271 
IFN-γ expression (Figure 5i, Supplementary Figure 4a). Conversely, neutralisation of 272 
IL-2 or IL-15, or IFN-αβR2 blockade, had no significant effect on NK cell activation in 273 
any NK cell subset (not shown). In summary, these data suggest optimal NK cell CD25 274 
and CD107a expression in response to EBOV GP stimulation is dependent on myeloid 275 
cell-derived IL-18 and IL-12. 276 
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As both IL-12 and IL-18 were not amenable to detection by Luminex assay of cell 277 
culture supernatants, we next sought to measure these responses to EBOV GP using 278 
high sensitivity ELISA for secreted IL-18 and flow cytometry for intracellular IL-12 279 
(gating strategy shown in Supplementary Figure 5a). There was a significant increase 280 
in IL-18 measured in supernatant after 18 hours stimulation with EBOV GP (median 281 
47.6pg/ml, range 16.8-183.5pg/ml) (Figure 5j), which correlated significantly with 282 
increasing NK cell CD25 expression (Figure 5k). We were able to detect IL-12(p40)+ 283 
cells by flow cytometry with significantly higher frequencies of IL-12(p40)+ cells in 284 
CD14-CD11c+ myeloid DCs (mDC) (30), total CD14- cells and CD14+ monocytes 285 
compared with medium alone. The highest frequencies of IL-12(p40)+ cells were 286 
observed in the CD14+ monocyte population (0.22%) (Figure 5L), consistent with the 287 
recovery of NK cell CD107a and CD25 responses by purified NK cells in the presence 288 
of this cell population.  289 
 290 
Regulation of NK cell IFN-γ production by EBOV GP induced IL-10. 291 
IL-10 is an essential immunoregulatory cytokine that is typically upregulated in 292 
response to inflammation (31). Having detected very high concentrations of IL-10 in 293 
supernatants of EBOV GP-stimulated PBMCs (Figure 4a) we explored the relationship 294 
between IL-10 production and NK cell function. NK cell IFN-γ expression significantly 295 
negatively correlated with IL-10 secretion in 18-hour cultures in both baseline (r=-296 
0.331, p=0.0218) (Figure 6a) and 21-day post-dose 2 PBMC (r=-0.324, p=0.0157; not 297 
shown) suggesting that IL-10 induced by EBOV GP might restrict the NK cell IFN-γ 298 
response. Therefore, PBMC from (non-vaccinated) control subjects were cultured for 299 
18 hours with EBOV GP in the presence of a blocking monoclonal antibody to the IL-300 
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10 receptor (IL-10R) or the appropriate isotype control antibody. IL-10R blockade 301 
resulted in significantly higher frequencies of IFN-γ+ (Figure 6b) and CD25+ (Figure 302 
6c) NK cells (and a significant increase in CD25 MFI; median 349.5 with IL-10R 303 
blockade; 110.5 with isotype control; p=0.0002; not shown) compared with isotype 304 
control treated cultures. CD107a was significantly enhanced by IL-10R blockade in the 305 
CD56dimCD57+ NK cell subset only (Supplementary Figure 4b), and IL-10R blockade 306 
particularly enhanced IFN-γ responses in CD56bright and CD56dimCD57- NK cell 307 
populations (Supplementary Figure 4b). 308 
We also investigated whether serum components, such as IL-18 binding proteins, may 309 
restrict IL-18-dependent responses to EBOV GP in some individuals. Overall, in vitro 310 
NK cell responses to EBOV GP were minimally affected by high concentrations of pre 311 
or post-Ad26.ZEBOV, MVA-BN-Filo vaccination serum (up to concentrations of 25% 312 
v/v) except CD25 expression was partially inhibited in the CD56bright NK cell population 313 
(Supplementary Figure 6a-d). In contrast, induction of CD25 by exogenous IL-18 was 314 
almost fully inhibited in the presence of high concentrations of serum, consistent with 315 
a potential role for IL-18BP in limiting the activity of IL-18. However, NK cell activation 316 
by a cocktail of IL-18 and IL-12 was only partially inhibited at high serum concentration 317 
(Supplementary Figure 6f, g).  318 
To determine the cellular source of the cytokines induced by EBOV GP, PBMC were 319 
cultured with EBOV GP for 18 hours, stained for intracellular IL-10, GM-CSF and TNF-320 
α and analysed by flow cytometry (gating strategy shown in Supplementary Figure 321 
5a). IL-10 was expressed predominantly in CD14+ monocytes (median 6.0%) with little 322 
or no evidence of expression in B cells, mDCs, CD14-, NK cells or T cells (Figure 6e). 323 
Back-gating confirmed that the majority of IL-10+ cells were CD19-CD14+ monocytes 324 
(Figure 6f) which is consistent with the lack of recovery of IFN-γ responses in purified 325 
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NK cells co-cultured with CD14+ monocytes (Figure 5a). GM-CSF expression was also 326 
essentially restricted to monocytes whereas the frequencies of TNF-α was similar in 327 
mDCs and monocytes (Supplementary Figure 5b, c). In summary, monocytes are the 328 
predominant source of inflammatory cytokines in response to EBOV GP in primary 329 
peripheral blood and monocyte-derived IL-10 negatively regulates NK cell IFN-γ 330 
secretion and CD25 expression. This immediate, robust IL-10 response could 331 
potentially explain the lack of IFN-γ expression by NK cells in response to EBOV GP 332 
both before and after vaccination (Figure 2). 333 
 334 
EBOV GP-induced NK cell activation is TLR-4 dependent. 335 
EBOV GP stimulates cytokine secretion in human monocytic cell lines and in vitro 336 
generated monocyte-derived DCs and macrophages in a TLR-4-dependent fashion 337 
(14-17). TLR-4 is expressed at high levels on human peripheral blood monocytes, as 338 
well as other myeloid lineage cells including macrophages and granulocytes (32). We 339 
therefore assessed the effect of blocking TLR-4 on cytokine secretion (measured by 340 
Luminex) and NK cell activation (by flow cytometry) in response to EBOV GP within 341 
PBMC from (non-vaccinated) control subjects. TLR-4 blockade significantly reduced 342 
secretion of IL-10 (0.3 fold-reduction; 7 of 7 donors) (Figure 7a), IL-1β, GM-CSF and 343 
IFN-γ but had no overall effect on IFN-α2 or TNF-α secretion (Figure 7b). Parallel 344 
effects were observed among NK cells where there was a partial, but significant, 345 
decrease in frequencies of IFN-γ+ (median 49.6% decrease in frequency) and CD25+ 346 
(median 14.6% decrease in frequency) CD56bright NK cells in the presence of TLR-4 347 
blocking antibodies (Figure 7c, d). Overall, these data indicate that NK cell activation 348 
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by EBOV GP is mediated, at least in part, via ligation of TLR-4 on primary human 349 
monocytes and the induction of cytokines.  350 
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Discussion 351 
In the 2014-2016 Ebola virus outbreak in West Africa, almost 30,000 cases of EVD 352 
were reported with more than 11,000 deaths (33). In 2019, Ebola virus continues to 353 
be a considerable global health concern, with the second largest outbreak on record 354 
currently ongoing in the Democratic Republic of the Congo (34). Detailed 355 
understanding of the immune response to Ebola virus infection and mechanisms of 356 
protection induced by Ebola virus vaccines would assist in efforts of prevention and 357 
containment of future outbreaks. We analysed the effect of the heterologous 2-dose 358 
Ad26.ZEBOV, MVA-BN-Filo vaccine regimen on human NK cell phenotype ex vivo 359 
and primary human innate cell function in response to soluble EBOV GP in vitro. We 360 
demonstrate NK cell activation, proliferation and expansion of less differentiated NK 361 
cells and found that, independently of vaccination, CD14+ monocytes are key 362 
responders to Ebola virus GP, rapidly producing a range of inflammatory cytokines in 363 
a manner that is partially dependent on TLR-4. Subsequent NK cell activation and 364 
function, dependent on myeloid cell-derived IL-12 and IL-18, was almost completely 365 
abrogated by the very high levels of IL-10 secreted as part of the acute myeloid cell 366 
response to EBOV GP in vitro.  367 
Activation and proliferation of NK cells after vaccination has been demonstrated with 368 
both inactivated and live attenuated vaccines. Jost et al demonstrated upregulation of 369 
CD69 and CD25 and increased numbers of CD56bright NK cells at day 4 post-influenza 370 
vaccination (26) and Marquardt et al. observed heightened NK cell Ki67 expression 371 
(peaking at day 10) after yellow fever vaccination (27). We have previously 372 
demonstrated increased percentages and proliferation of CD56bright NK cells at day 3 373 
and up to 4 weeks after influenza vaccination (28). Our ex vivo data demonstrate 374 
activation of less differentiated NK cells by a vectored, Ebola GP-expressing vaccine. 375 
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We detected heightened CD56bright NK cell proliferation up to 78 days after first 376 
vaccination (21 days post-dose 2) and an increase in the proportion of CD56bright NK 377 
cells from as early as day 15 post-dose 1 until at least 21 days post-dose 2. Increased 378 
expression of CD25 by NK cells post-vaccination may indicate the potential for T cell 379 
derived IL-2 to contribute to NK cell proliferation and activation (28, 35, 36). 380 
The pathogenesis of EVD is closely linked to the very high levels of pro-inflammatory 381 
cytokines induced by the infection (13, 19, 20). We show for the first time within primary 382 
human PBMC cultures, that Ebola GP stimulated the secretion of high levels of IL-1β, 383 
GM-CSF and TNF-α independently of vaccination. This inflammatory response was 384 
accompanied by an equally rapid and potent IL-10 response and somewhat lower 385 
levels of IL-12, IL-18 and IFN-α2. These data - in a highly relevant ex vivo system – 386 
corroborate previous observations from human cell lines and in vitro generated 387 
monocyte-derived DCs and macrophages (11, 14, 16, 18). The relatively low levels of 388 
NK cell and T cell-activating cytokines together with the abundance of IL-10 suggest 389 
the generation of a tightly regulated cytokine environment within hours of exposure to 390 
soluble EBOV GP. Rapid production of IL-10 in response to a potent pro-inflammatory 391 
stimulus is a well-described feature of the human homeostatic response; in preventing 392 
a life-threatening cytokine storm, this can also influence the emerging adaptive 393 
response (31). Indeed, pro and anti-inflammatory cytokines both indirectly correlate 394 
with survival after EVD indicating that IL-10 itself, although associated with anti-395 
inflammatory properties does not predict protection from disease (13).  396 
Innate, pro-inflammatory cytokine responses are also regulated by specific cytokine- 397 
binding serum proteins, including IL-18 binding protein (IL-18bBP) (37). We observed 398 
that high concentrations (up to 25% v/v) of serum (pre- or post-vaccination) inhibited 399 
the NK cell CD25 response to rIL-18 (as expected) but had rather little effect on the 400 
 20 
response to cytokine cocktails (e.g. rIL-18 plus rIL-12) or EBOV GP suggesting that  401 
while IL-18BP may limit the effects of IL-18 it may have less impact on the much lower, 402 
synergistic, combinations of cytokines induced by, for example, a viral infection or on 403 
the cell-contact mediated events at the NK cell-monocyte synapse. Additionally, our 404 
data demonstrate reduction of CD25 and degranulation responses in post-dose 2 405 
vaccination serum compared with pre-vaccination serum in some individual vaccinees, 406 
consistent with a potential role for vaccine-induced antibody in blocking EBOV GP-407 
TLR-4 interactions at higher serum concentrations. 408 
CD14+ monocytes were the main source of both inflammatory and anti-inflammatory 409 
cytokines within hours of EBOV GP stimulation. Both types of monocyte response and 410 
the downstream NK cell response were TLR-4-dependent confirming prior studies 411 
showing Ebola virus GP is recognised by TLR-4 inducing inflammatory cytokine 412 
secretion (14, 16, 17, 38). We demonstrate indirect, innate cytokine-dependent NK 413 
cell effector function in response to Ebola virus GP in human PBMC in vitro culture, 414 
independent of prior Ad26.ZEBOV, MVA-BN-Filo vaccination. IL-18 and to a lesser 415 
extent, IL-12, from myeloid accessory cells were required for optimal NK cell 416 
degranulation and CD25 upregulation. This innate response, which is particularly 417 
enriched in less differentiated NK cell subsets, is consistent with the proliferation and 418 
activation of the least differentiated, CD56bright NK cells after vaccination itself 419 
(measured ex vivo). This suggests that, as seen in vitro, expression of Ebola GP by 420 
vaccination could potentially stimulate innate, cytokine-dependent NK cell activation 421 
in vivo.  422 
Innate NK cell activation in response to EBOV GP, with an apparent lack of 423 
enhancement of NK cell responses post-vaccination, is in complete contrast to 424 
previous observations with yellow fever, BCG and influenza vaccination (27, 28, 39). 425 
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It is well established that enhanced NK cell responses after vaccination, are mediated 426 
in part by IL-2 from antigen-specific T cells and vaccine induced antibody (27, 28, 35, 427 
39-41). Despite evidence of moderate induction of IL-2+IFN-γ+TNF-α+ triple positive T 428 
cells and the presence of 1% post-Ad26.ZEBOV, MVA-BN-Filo vaccination serum (5), 429 
there was no enhancement of the NK cell response, or downregulation of CD16 in 430 
response to EBOV GP post-vaccination compared with baseline. Plausibly, the lack of 431 
post-vaccination NK cell enhancement in vitro may be linked to the effects of 432 
monocyte-derived IL-10. A system-wide analysis of the immune response to the rVSV-433 
ZEBOV Ebola vaccine suggested negative regulation by inflammatory monocytes 434 
(22), additionally, IL-10 blockade restored antigen-specific T cell-derived IL-2-435 
dependent activation of NK cells in other viral infection models (42, 43).  436 
In summary, we have characterised the NK cell response to the novel 2-dose 437 
Ad26.ZEBOV, MVA-BN-Filo vaccination regimen. We also demonstrate that the 438 
robust TLR-4-dependent, monocyte-derived, innate cytokine response to Ebola GP 439 
both stimulates and regulates the NK cell effector response. This study contributes to 440 
our understanding of immune responses induced by Ebola vaccines and demonstrates 441 
that innate cytokine responses induced by Ebola GP may be integral to the induction 442 
and regulation of NK cell function after vaccination.443 
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 Materials and Methods 444 
Study participants and samples 445 
Cryopreserved PBMCs (with corresponding serum samples) from healthy adults, aged 446 
18 to 50 years (median 39 years), were obtained from participants enrolled in the 447 
EBL1001 single-centre, randomised, placebo-controlled, observer blind trial 448 
conducted in Oxford, U.K. as described (ClinicalTrials.gov Identifier: NCT02313077) 449 
(5). Participants were randomised into four groups, with a fifth group subsequently 450 
added by a protocol amendment, to receive the Ad26.ZEBOV, MVA-BN-Filo vaccine 451 
according to one of five vaccination schedules (Table 1). The vaccine comprises 452 
monovalent Ad26.ZEBOV expressing the GP of the Ebola Zaire virus (Mayinga 453 
variant) (Janssen Vaccines and Prevention B.V., The Netherlands) and multivalent 454 
MVA-BN-Filo expressing the GP of the Sudan and Zaire Ebola viruses and Marburg 455 
virus together with Tai Forest virus nucleoprotein (Bavarian Nordic, Denmark). Groups 456 
1 and 2 received MVA-BN-Filo on day 1 and Ad26.ZEBOV on either day 29 or 57 457 
respectively; groups 3, 4 and 5 received Ad26.ZEBOV on day 1 and MVA-BN-Filo on 458 
days 29, 57 or 15 respectively.  459 
Samples from 70 donors (non-placebo arms) were obtained from pre-vaccination 460 
(baseline, visit 0), post-dose 1 (day 29, 57 or 15 depending on group; visit 1) and 21 461 
days post-dose 2 (day 50, 78 or 36 depending on group; visit 2) (Table 1). Human 462 
cytomegalovirus (HCMV) serology was conducted on the baseline serum sample of 463 
each donor by HCMV IgG ELISA (Demeditec, Kassel, Germany); 26 of 70 volunteers 464 
(37%) were HCMV seropositive, 44 were HCMV seronegative and two were 465 
indeterminate. Additional non-vaccinated, healthy, adult volunteers (n=16) were 466 
recruited for subsequent in vitro experiments from among staff and students at the 467 
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London School of Hygiene and Tropical Medicine (LSHTM) using an anonymised 468 
volunteer database.  469 
In vitro cellular assays 470 
Cryopreserved PBMCs were thawed, washed in RPMI 1640 supplemented with 471 
100U/ml penicillin/streptomycin and 20mM L-glutamine (Gibco, ThermoFisher) and 472 
rested for 2 hours. The average cell yield after thaw was 5.8x106 per vial (58% 473 
recovery). Fresh PBMC were isolated from heparinised whole blood using Histopaque 474 
1077 (Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation. All cells were counted 475 
using Fastread counting slides (ImmuneSystems, U.K.). Trial PBMC were stained 476 
immediately ex vivo or cultured in 96-well round-bottom plates in RPMI 1640 477 
supplemented as above and with 1% autologous (pre, post-dose 1 or post-dose 2) 478 
serum and 10μg/ml purified recombinant Ebola virus GP (EBOV GP), Mayinga variant, 479 
prepared in Hek293F cells (Janssen Vaccines and Prevention B.V.) for 8 and 18 hours 480 
at 37°C. 481 
For additional 18-hour experiments, fresh PBMC from non-trial donors were stimulated 482 
with 10μg/ml EBOV GP or cytokines alone; IL-12; 5ng/ml (PeproTech, London, U.K.) 483 
and/or IL-18; 10 or 50ng/ml (R&D Systems, Oxford, U.K.) in RPMI supplemented as 484 
above and with 5% FCS, or 1, 5, or 25% pooled pre or post-vaccination serum. The 485 
following blocking antibodies or isotype control antibodies were used, all at 3μg/ml; 486 
anti-IL-2 (Becton Dickinson (BD) Biosciences, Oxford, U.K.), anti-IL-10R (Biolegend), 487 
rat IgG2a isotype control (eBiosciences, ThermoFisher), anti-IL-12 (BD Biosciences), 488 
anti-IL-15 (eBiosciences), anti-IL-18 (MBL, U.S.A), mouse IgG1 isotype control 489 
(eBiosciences). Anti-IFN-αβR2 (Merck Millipore, Watford, U.K.) and mouse IgG2a 490 
isotype control (eBiosciences) were used at a final concentration of 1μg/ml. In vitro 491 
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blockade of TLR-4 was performed in the presence of 5μg/ml anti-TLR-4 rabbit 492 
polyclonal anti-sera or isotype matched control reagent with irrelevant specificity 493 
(Invivogen, U.K.).  494 
To determine accessory cell dependency, NK cells and CD14+ monocytes were 495 
purified by magnetic bead separation (MACS) using NK Cell Isolation Kit (Miltenyi 496 
Biotec, Germany) (NK cells 90.2%3.2% pure) and Pan Monocyte Isolation Kit 497 
(Miltenyi Biotec) (monocytes 62.8%11% pure with less than 1% NK cell 498 
contamination), respectively. Cells were cultured as above for 18 hours in 5% FCS 499 
(n=5). GolgiPlug (Brefeldin A; 1/1000 final concentration; BD Biosciences) and 500 
GolgiStop (Monensin; 1/1500 concentration; BD Biosciences) were added to all in vitro 501 
cultures for the final 3 hours of culture. Cells were then stained with fluorophore 502 
labelled antibodies for flow cytometry and culture supernatants were collected and 503 
stored at -80°C for cytokine analysis by Luminex/ELISA. 504 
Flow cytometry 505 
Cells were stained for surface markers including a viability marker (Fixable Viability 506 
Stain 700; BD Biosciences) in FACS buffer (PBS, 0.5% FCS, 0.05% sodium azide and 507 
2mM EDTA) for 30 minutes in 96-well round bottom plates after blocking Fc receptors 508 
for 5 minutes with Fc Receptor (FcR) Blocking Reagent (Miltenyi Biotec). Cells were 509 
then washed in FACS buffer, fixed and permeabilised using Cytofix/Cytoperm Kit (BD 510 
Biosciences) or Foxp3/Transcription Factor Fixation/Permeabilisation Kit 511 
(eBiosciences) according to the manufacturer’s instructions. Cells were then stained 512 
for intracellular markers with FcR blocking for 20 minutes and washed again. Finally 513 
cells were resuspended in FACS buffer and analysed using a BD LSRII flow 514 
cytometer. Cells were acquired using FACSDiva software and data were analysed 515 
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using FlowJo V10 (Tree Star, Oregon, U.S.A). FACS gates were set using 516 
unstimulated cells or FMO controls. Samples with less than 100 NK cell events were 517 
excluded from the analysis (<4% of samples evenly distributed across all groups). 518 
The following fluorophore labelled antibodies were used: anti-CD3-V500 (clone 519 
UCHT1) (BD Biosciences), anti-CD56-BV605 (clone HCD56), anti-IFN-γ-BV785 520 
(clone 4S.B3), anti-IFN-γ-APC (clone 4S.B3), anti-CD25-BV785 (clone BC96), anti-521 
CD11c-BV785 (clone 3.9), anti-CD14-AF700 (clone 63D3), anti-GM-CSF-PE-Dazzle 522 
(clone BVD2-21C11), anti-TNF-α-FITC (clone MAb11), anti-IL-10-PE (clone JES3-523 
9D7) (all Biolegend, London, U.K.). Anti-CD16-APC (clone CB16), anti-CD25-524 
PerCPCy5.5 (clone BC96), anti-CD57-e450 (clone TB01), Ki67-PerCP-eFluor710 525 
(clone 20Raj1), anti-CD19-PECy7 (clone HIB19), anti-IL-12-eFlour660 (clone C8.6) 526 
(all eBiosciences), anti-NKG2A-PE-Vio770 (clone REA110) (Miltenyi Biotec), anti-527 
NKG2C-PE (clone 134591) (R&D systems). Anti-CD107a-FITC (clone H4A3) (BD 528 
Biosciences) was added to the culture at 2l per 100l for the whole culture period.  529 
Luminex and IL-18 ELISA  530 
Concentrations of GM-CSF, IFN-α2, IFN-γ, TNF-α, IP-10, IL-1β, IL-10, IL-12p70, IL-531 
15 in cell culture supernatants were determined by Luminex technology (Merck 532 
Millipore) using the xPONENT 4.1 software for data acquisition. The concentration of 533 
IL-18 was determined by ELISA (R&D Systems). 534 
Statistics 535 
Statistical analysis was performed using GraphPad Prism version 7.04 (GraphPad, 536 
California, U.S.A.). Functional responses were compared using Wilcoxon signed-rank 537 
test or one-way ANOVA Friedman test with Dunn’s correction for multiple 538 
comparisons. For correlation analysis, a linear regression model was fitted in prism 539 
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and r and p values were determined using Spearman’s correlation analysis. 540 
Significance levels are assigned as *p, <0.05, **p, <0.01, ***p, <0.001, and ****p, 541 
<0.0001 for all tests. 542 
Study approval 543 
Written informed consent was received from all participants prior to inclusion in the 544 
study. The trial protocol and study documents were approved by the National 545 
Research Ethics Service (reference number 14/SC/1408) and the LSHTM Research 546 
Ethics Committee (reference number 14383).  547 
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Figures and legends 718 
 719 
Figure 1. Robust NK cell responses to Ad26.ZEBOV, MVA-BN-Filo vaccination 720 
measured ex vivo. 721 
NK cell phenotype at baseline (visit 0), visit 1 (day 29, 57 or 15 post-dose 1) and visit 722 
2 (21 days post-dose 2) was analysed ex vivo by flow cytometry (gating strategy is 723 
shown in Supplementary Figure 1), n=70. Frequencies of CD56bright and CD56dim (a), 724 
CD56bright Ki67+, CD56dimCD57- Ki67+ and CD56dimCD57+ Ki67+ (b), NKG2A+ and 725 
NKG2C+ (c), CD56bright CD25+ and CD56dim CD25+ NK cells (d) were determined. The 726 
correlation between total NK cell CD25 and Ki67 expression at 21 days post-dose 2 727 
(e) was also determined by Spearman’s coefficient. Graphs show box and whisker 728 
plots with median, interquartile range (IQR) (box) and 10th-90th percentile (whiskers). 729 
Comparisons across vaccination visits were performed using one-way ANOVA with 730 
Dunn’s correction for multiple comparisons. *p <0.05, **p <0.01, ***p <0.001. 731 
 732 
 36 
 733 
Figure 2. NK cell CD107a and CD25, but not IFN-γ expression upregulation in 734 
response to EBOV GP stimulation in vitro. 735 
Whole PBMC from baseline (visit 0), visit 1 (day 29, 57 or 15 post-dose 1) and visit 2 736 
(21 days post-dose 2) were stimulated with EBOV GP or left unstimulated (medium) 737 
for 8 and 18 hours in the presence of 1% autologous serum, n=70. Cells were stained 738 
for NK cell activation markers and analysed by flow cytometry. Frequencies of CD107a 739 
and IFN-γ, measured at 8 hours or CD25 and CD16 measured at 18 hours, within total 740 
live CD3-CD56+ NK cells were gated using medium alone controls, plots shown from 741 
one representative donor (a). Graphs show NK cell CD107a (b), IFN-γ (c), CD25 (d) 742 
and CD16 (d) expression as one point per donor with a line representing the median. 743 
Comparisons across vaccination visits were performed using one-way ANOVA with 744 
Dunn’s correction for multiple comparisons and between conditions by Wilcoxon 745 
signed-rank test. ****p <0.0001. 746 
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 747 
Figure 3. Less differentiated NK cells respond strongly to EBOV GP stimulation in 748 
vitro. 749 
NK cell IFN-γ (a) and CD107a (b), measured at 8 hours and CD25 (c), measured at 750 
18 hours in response to medium alone and EBOV GP in baseline (visit 0) samples 751 
only was analysed according to NK cell differentiation subset determined by CD56 and 752 
CD57 expression (CD56bright, CD56dimCD57-, CD56dimCD57intermediate (int) and 753 
CD56dimCD57+), n=70. The proportion of CD25+ NK cell events per subset determined 754 
by back-gating is also shown as a pie chart (d). Graphs show one point per donor with 755 
a line representing the median. Comparisons across NK cell subsets were performed 756 
using one-way ANOVA with Dunn’s correction for multiple comparisons and between 757 
conditions by Wilcoxon signed-rank test. *p <0.05, **p <0.01, ***p <0.001, ****p 758 
<0.0001. 759 
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Figure 4. High concentrations of inflammatory cytokines induced by EBOV GP 761 
stimulation in vitro. 762 
Supernatants were collected from baseline (visit 0) and post-dose 2 (visit 2) PBMC 763 
after 18 hours stimulation with EBOV GP or medium alone and concentrations of IL-764 
10 (a), IL-1β (b), IFN-α2 (c), GM-CSF (d), TNF-α (e) and IFN-γ (f) were determined by 765 
Luminex, n=70. Graphs show one point per donor with the median and IQR. 766 
Comparisons were performed using one-way ANOVA with Dunn’s correction for 767 
multiple comparisons. *p <0.05, ***p <0.001, ****p <0.0001. 768 
 769 
 770 
 771 
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Figure 5. Myeloid accessory cell cytokine dependent NK cell activation. 773 
Non-vaccinated control PBMC, purified NK cells or purified NK cells plus CD14+ 774 
monocyte enriched population (mono) were stimulated with EBOV GP, n=5 (a-c). 775 
PBMC were also left unstimulated or stimulated with EBOV GP in the presence of 776 
blocking antibodies against IL-12 and IL-18 or appropriate isotype control (Iso.), n=16. 777 
NK cell function was analysed by flow cytometry. Graphs show CD56bright IFN-γ, 778 
CD107a and CD25 expression (a-c), total NK cell CD25 MFI (d) or percentage (e) or 779 
CD56bright CD25 MFI (f) or percentage (g) and total NK cell CD107a (h) and IFN-γ 780 
expression (i). Concentrations of IL-18 in culture supernatant and intracellular IL-12 781 
expression were determined by ELISA and flow cytometry respectively, the 782 
relationship between IL-18 and total NK cell CD25 expression was determined by 783 
Spearman’s coefficient (j-l). IL-12(p40)+ B cells (CD19+), myeloid DC (mDC; CD19-784 
CD14-CD11c+), total CD14- and total CD14+ cells were gated as per gating strategy in 785 
Supplementary Figure 5a. Graphs show box and whisker plots with median, IQR (box) 786 
and 10th-90th percentile (whiskers) or one point per donor. Comparisons were 787 
performed using Wilcoxon signed-rank test and correlations were determined using 788 
Spearman’s correlation. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. 789 
 790 
 791 
 792 
 793 
 794 
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 796 
Figure 6. Regulation of NK cell IFN-γ production by EBOV GP induced IL-10. 797 
The correlation between NK cell IFN-γ secretion determined by intracellular staining 798 
and IL-10 secretion measured by Luminex in response to EBOV GP (in baseline trial 799 
samples) was determined by Spearman’s coefficient, n=70 (a). Non-vaccinated control 800 
PBMC were stimulated in the presence of blocking antibodies against IL-10R or 801 
isotype control, n=16. Total NK cell IFN-γ (b), CD107a (c) and CD25 (d) expression 802 
was determined. Intracellular IL-10 was also measured by flow cytometry (gating 803 
strategy as per Supplementary Figure 5a) in B cells (CD19+), myeloid DC (mDC; 804 
CD14-CD11c+), total CD14- and total CD14+ cells, NK cells (CD3-CD56+) and T cells 805 
(CD3+) (e). The proportion of IL-10+ events per cell type determined by back-gating is 806 
also shown as a pie chart (f). Graphs show box and whisker plots with median, IQR 807 
(box) and 10th-90th percentile (whiskers). Comparisons were performed using 808 
Wilcoxon signed-rank test. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. 809 
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Figure 7. EBOV GP induced NK cell activation is dependent on interaction with TLR-811 
4. 812 
Non-vaccinated control PBMC were stimulated in the presence of blocking antibodies 813 
against TLR-4 or isotype control, n=16. Supernatants were collected and 814 
concentrations of IL-10, IL-1β, GM-CSF, IFN-γ, IFN-α2 and TNF-α were measured by 815 
Luminex. Graphs show IL-10 concentration as one dot per donor (n=7 with values 816 
below Luminex cut-off value of 10,000pg/ml) (a) and IL-1β, GM-CSF, IFN-γ, IFN-α2 817 
and TNF-α as fold change between isotype control and TLR-4 blockade (b). 818 
Expression of CD56bright NK cell IFN-γ (c) CD25 (d) were determined after 18 hours by 819 
flow cytometry. Graphs show one point per donor (IL-10), median with IQR (remaining 820 
cytokines) or box and whisker plots with median, IQR (box) and 10th-90th percentile 821 
(whiskers). Comparisons between conditions were performed using Wilcoxon signed-822 
rank test. *p <0.05, ***p <0.001, ****p <0.0001.  823 
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Table 1: Vaccination schedule of each group and samples received (PBMC and 824 
corresponding serum).  825 
  Samples received: 
Group (n) Vaccine 
schedule 
Baseline 
(Visit 0) 
Post-dose 1 
(Visit 1) 
Post-dose 2 
(Visit 2) 
Group 1 (n=15) MVA, Ad26 Day 1 Day 29 Day 50 
Group 2 (n=15) MVA, Ad26 Day 1 Day 57 Day 78 
Group 3 (n=14) Ad26, MVA Day 1 Day 29 Day 50 
Group 4 (n=14) Ad26, MVA Day 1 Day 57 Day 78 
Group 5 (n=12) Ad26, MVA Day 1 Day 15 Day 36 
 826 
